13 April 2024
: Case report
Successful Superficial Blood Sampling to Localize a Fibroblast Growth Factor-23-Producing Tumor
Challenging differential diagnosis, Unusual setting of medical care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Junjiro Rikitake1ABCDEF, Kenji AshidaDOI: 10.12659/AJCR.943152
Am J Case Rep 2024; 25:e943152
Table 1. Laboratory data on admission.
| Parameters | Values | Reference range |
|---|---|---|
| Protein, mg/dL | Negative | |
| Total protein, g/dL | 6.6 | 6.6–8.1 |
| Albumin, g/dL | 4.1–5.1 | |
| BUN, mg/dL | 16 | 8–20 |
| Cre, mg/dL | 0.87 | 0.65–1.07 |
| Uric acid, mg/dL | 5.6 | 3.7–7.0 |
| Sodium, mmol/L | 141 | 138–145 |
| Potassium, mmol/L | 4.2 | 3.6–4.8 |
| Chloride, mmol/L | 106 | 101–108 |
| FPG, mg/dL | 91 | 70–109 |
| CRP, mg/dL | <0.04 | <0.14 |
| Intact-PTH, pg/mL | 40.9 | 10.0–65.0 |
| Intact FGF-23, pg/mL | 19.9–52.9 | |
| 1,25 (OH) D, pg/mL | 24.2 | 20.0–60.0 |
| 25 (OH) D, ng/mL | ≥30 | |
| Total P1NP, ng/mL | 18.1–74.1 | |
| Occult blood | – | Negative |
| AST, IU/L | 24 | 13–30 |
| ALT, IU/L | 23 | 10–30 |
| ALP, U/L | 38–113 | |
| CK, IU/L | 86 | 59–248 |
| LDL-cholesterol, mg/dL | 116 | 65–139 |
| Calcium, mg/dL | 8.7 | 8.8–10.1 |
| Phosphate, mg/dL | 2.7–4.6 | |
| HbA1c (NGSP), % | 5.8 | 4.9–6.0 |
| TSH, μU/mL | 0.870 | 0.500–5.000 |
| Free thyroxine, ng/dL | 1.16 | 0.93–1.70 |
| Free thyronine, pg/mL | 2.9 | 2.3–4.0 |
| TRACP-5b, mU/dL | 170–590 | |
| * Reference range that is supposed to be sufficient with vitamin D. CK – creatine kinase; Cre – creatinine; DEX – dexamethasone; FPG – fasting plasma glucose; HbA1c – hemoglobin A1c; CRP – C-reactive protein; P1NP – procollagen type 1 N-terminal propeptide; TRACP-5b – tartrate-resistant acid phosphatase 5b; TSH – thyroid-stimulating hormone; PTH – parathyroid hormone; BUN – blood urea nitrogen; AST – aspartate aminotransferase; ALT – alanine aminotransferase; LDL – low-density lipoprotein. | ||






